KRAS and neoplasm: K-RasG12C is the common mutation activating K-Ras, whose inhibitors are scheduled to be put into clinical use in different types of tumor this year; given this, we chose inhibitor 9 as K-RasG12C inhibitor for in vitro and in vivo evaluation.